PATIENT PREFERENCES FOR AMYLOID-TARGETING THERAPIES OF ALZHEIMER’S DISEASE IN CHINA...
Author(s)
Haipeng Wang, PhD, Jingyi Liang, MS, lei dou, PhD, Shunping Li, PhD.
Shandong University, Jinan, China.
Shandong University, Jinan, China.
OBJECTIVES: Alzheimer's disease (AD) imposes profound clinical and societal burdens. Treatment decisions for novel amyloid-targeting therapies involve complex trade-offs between efficacy, safety, and out-of-pocket costs. Yet, patient preferences regarding these attributes are rarely quantified in China. This study aimed to elicit Chinese patients' preferences for key AD treatment attributes.
METHODS: A discrete choice experiment (DCE) involving 150 early-stage AD patients was conducted to elicit treatment preferences. The survey incorporated six attributes identified via literature review and expert consensus, including administration frequency, duration of delayed progression, 1-year probability of stabilized progression, ARIA risk, MRI monitoring frequency, and annual out-of-pocket costs. Data from face-to-face interviews were analyzed using mixed logit models to quantify relative attribute importance, minimum acceptable benefit, and willingness to pay.
RESULTS: AD patients significantly preferred longer disease progression delays and higher efficacy probabilities (P < 0.01). Annual out-of-pocket cost was the primary decision driver (relative importance [RI]: 50.2%), followed by progression delay duration (26.1%) and 1-year stabilization probability (8.1%). Patients required a minimum acceptable benefit of 3.85 additional months of delayed progression to accept a 10% increase in adverse event risk, with a willingness-to-pay of ¥38,900 per year for a 12-month delay. Subgroup analyses revealed preference heterogeneity: higher-income and more educated patients placed greater importance on efficacy magnitude, while older patients (≥70 years) prioritized the probability of achieving efficacy (RI: 24.5% vs. 9.4%).
CONCLUSIONS: While high out-of-pocket costs present a major barrier to novel AD therapies in China, patients place substantial value on delaying disease progression, demonstrating a clear willingness to accept safety risks for clinical efficacy. Ultimately, integrating these preference data into shared decision-making and health technology assessments will be essential for optimizing patient-centered care and value-based resource allocation.
METHODS: A discrete choice experiment (DCE) involving 150 early-stage AD patients was conducted to elicit treatment preferences. The survey incorporated six attributes identified via literature review and expert consensus, including administration frequency, duration of delayed progression, 1-year probability of stabilized progression, ARIA risk, MRI monitoring frequency, and annual out-of-pocket costs. Data from face-to-face interviews were analyzed using mixed logit models to quantify relative attribute importance, minimum acceptable benefit, and willingness to pay.
RESULTS: AD patients significantly preferred longer disease progression delays and higher efficacy probabilities (P < 0.01). Annual out-of-pocket cost was the primary decision driver (relative importance [RI]: 50.2%), followed by progression delay duration (26.1%) and 1-year stabilization probability (8.1%). Patients required a minimum acceptable benefit of 3.85 additional months of delayed progression to accept a 10% increase in adverse event risk, with a willingness-to-pay of ¥38,900 per year for a 12-month delay. Subgroup analyses revealed preference heterogeneity: higher-income and more educated patients placed greater importance on efficacy magnitude, while older patients (≥70 years) prioritized the probability of achieving efficacy (RI: 24.5% vs. 9.4%).
CONCLUSIONS: While high out-of-pocket costs present a major barrier to novel AD therapies in China, patients place substantial value on delaying disease progression, demonstrating a clear willingness to accept safety risks for clinical efficacy. Ultimately, integrating these preference data into shared decision-making and health technology assessments will be essential for optimizing patient-centered care and value-based resource allocation.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
PCR5
Topic
Patient-Centered Research
Disease
SDC: Neurological Disorders